http://www.xconomy.com/boston/2009/03/31/genzyme-gene-therapy-fails-to-help-people-with-leg-disease-walk-longer/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 03:54:18 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/boston/2009/03/31/genzyme-gene-therapy-fails-to-help-people-with-leg-disease-walk-longer/comment-page-1/#comment-112174 Genzyme Gene Therapy Fails To Help People with Leg Disease Walk Longer | Xconomy | .gen Technologies Inc. Mon, 01 Mar 2010 20:52:57 +0000 http://www.xconomy.com/?p=18307#comment-112174 [...] http://www.xconomy.com/boston/2009/03/31/genzyme-gene-therapy-fails-to-help-people-with-leg-disease-... [...] [...] http://www.xconomy.com/boston/2009/03/31/genzyme-gene-therapy-fails-to-help-people-with-leg-disease-... [...]

]]> http://www.xconomy.com/boston/2009/03/31/genzyme-gene-therapy-fails-to-help-people-with-leg-disease-walk-longer/comment-page-1/#comment-52417 Genzyme in the News: Bayer Deal, Failed Gene Therapy Trial | IguanaBio - A Daily Biotech and Pharma Tabloid - Gossip, News, Humor and Updates on the Latest Events in the Biotechnology and Pharmaceutical Industries Tue, 31 Mar 2009 21:00:46 +0000 http://www.xconomy.com/?p=18307#comment-52417 [...] Genzyme also made some headlines this weekend on news of a failed gene therapy trial. Xconomy reported that the study looked at 289 patients with peripheral arterial disease (PAD) who were injected with either a placebo, low, medium, or high dose of a HIF-1 alpha gene. The treatment failed to show that it could increase treadmill walking time before disabling pain or fatigue caused patients to stop (intermittent claudication). Patients were examined at six months and followed for two years. The study was presented this past weekend at the American College of Cardiology annual meeting. [Xconomy] [...] [...] Genzyme also made some headlines this weekend on news of a failed gene therapy trial. Xconomy reported that the study looked at 289 patients with peripheral arterial disease (PAD) who were injected with either a placebo, low, medium, or high dose of a HIF-1 alpha gene. The treatment failed to show that it could increase treadmill walking time before disabling pain or fatigue caused patients to stop (intermittent claudication). Patients were examined at six months and followed for two years. The study was presented this past weekend at the American College of Cardiology annual meeting. [Xconomy] [...]

]]>